The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will test that hypothesis that topical administration of the FDA approved
immunomodulatory agent cyclosporin A emulsion will minimize irritation and ocular surface
disease that results from a short term low humidity environmental stress